# Lipid Nanoparticle (LNP) Characterization

LNPs are used to deliver cancer drugs and gene therapies:

- Doxil (liposomal doxirubicin, treats solid tumors)
- Marqibo (liposomal vincristine, treats acute lymphoblastic leukemia)
- Onpattro (siRNA, treats polyneuropathy caused by hereditary transthyretinmediated amyloidosis)
- SARS-CoV-2 vaccines (mRNA cargo, Covid-19 vaccines, Pfizer-Biontech, Moderna)



# Lipid Nanoparticle (LNP) Characterization by MW-AUC



Amy Henrickson, Univ. Lethbridge Dr. Pieter Cullis and Dr. Jayesh Kulkarni, University of British Columbia



www.acsnano.org

# Density Matching Multi-wavelength Analytical Ultracentrifugation to Measure Drug Loading of Lipid Nanoparticle Formulations

Amy Henrickson, Jayesh A. Kulkarni, Josh Zaifman, Gary E. Gorbet, Pieter R. Cullis, and Borries Demeler\*

ARTIC

ACS Nano 2021, 15, 5068-5076

# Measuring Lipid Nanoparticle loading with RNA

# Challenges:

- Heterogeneity in LNP size
- Heterogeneity in RNA loading
- Unknown amount of unincorporated RNA, if any
- Clinically relevant loaded LNPs and empty LNPs look identical in cryo-TEM
- DLS and SEC too low in resolution and don't differentiate by loading

## Focus on what's different:

- Liposomes and RNA have different
  absorbance spectra and densities
- Liposomes with different RNA loading ratios have different densities
- Different sizes have different
  hydrodynamic radii
- Liposomes with different sizes and different RNA loading will vary in *molar mass*

# **Experimental Design:**

- Measure Mie scattering and siRNA absorbance by MW-AUC
- SV-AUC differentiates based on s and D
- Perform D<sub>2</sub>O density matching
  - 1) obtain partial specific volume distributions
  - 2) derive molar mass distribution
  - 3) derive hydrodynamic radii
- Integrate constraints from orthogonal methods (cryo-TEM)

$$M = \frac{\mathbf{S} RT}{\mathbf{D}(1 - \overline{\mathbf{v}} \rho)}$$

# <u>Step 1:</u>

# Perform D<sub>2</sub>O density matching analysis Approach: Measure RNA control in 4 D<sub>2</sub>O Concentrations Derive partial specific volume distribution and heterogeneity

# <u>Step 2:</u>

# Repeat for Lipid Nanoparticle sample Derive molar masses and hydrodynamic radii distributions

# <u>Step 3:</u>

Perform MW-AUC experiment Deconvolute nucleic acids and liposome Validate partial specific volume distribution

#### Step 1: Measure RNA control in 4 D<sub>2</sub>O Concentrations



## Step 2: Create Integral G(s) Distributions:



#### Step 3: Determine s-values at each boundary fraction



# Step 3: Extrapolate equivalent boundary fractions to zero S



The inverse of the density at s=0 is equivalent to the partial specific volume at that boundary fraction. This can be repeated for each boundary fraction to derive a PSV distribution.

## **Repeat for each Lipid Nanoparticle Preparation:**



(Lipids are less dense than water or heavy water and float – negative s-values)

# Extrapolate each boundary fraction to zero sedimentation to derive the partial specific volume of this heterogeneous mixture:



#### ... or any other biopolymer:



## ...or any a different cargo (mRNA):



# ...or any a different cargo (mRNA):



# Report Particle Sizes based on known Anisotropy ( $\varphi$ ):



$$\phi = \frac{f}{f_0} = 1.0, \quad D = \frac{RT}{9\pi\eta\phi N} \left(\frac{2s\phi\,\overline{\nu}\,\eta}{1-\overline{\nu}\rho}\right)^{-0.5}$$

#### **Report Particle Sizes and Molar Masses:**



# Deconvolute Liposome Absorbance from RNA Absorbance:



UV spectral properties of RNA (green), empty LNP (red), and RNA-loaded LNPs (blue).

# Deconvolute Liposome Absorbance from RNA Absorbance:



Dashed Lines: Liposome scattering signal Solid Lines: RNA absorbance signal

NP1 at 260 nm, NP1 using fluorescence siRNA at 260 nm (2.58s)

# Software Demo – Custom Grid